Can CBD Alleviate the Symptoms of Epilepsy?

By | November 11th, 2016|Categories: Cannabis, Cannabis Oil, Cannabis Prohibiton, CBD, Children, Dravet Syndrome, Endocannabinoids, Epidiolex, Epilepsy, Featured News, Featured Research, GW Pharma, Legalisation, News, Research|Tags: , , , , |

There have been many examples in recent years of published scientific articles, which have been peer-reviewed, as well as news items in the more general press, which have indicated the broad range of medical conditions susceptible to treatment by cannabis and related compounds. Much publicity has been gained in particular for reports claiming [...]

Marijuana and Mental Health: The Miseducation Of Reefer Madness

By | November 3rd, 2016|Categories: Cancer, Cannabis, Cannabis Oil, Cannabis Prohibiton, CBD, Depression, Featured News, GW Pharma, Legalisation, Mental Health, News, Psychosis, Schizophrenia|

As anyone taking a modicum of notice will know, the UK currently finds itself in the grip of mental health crisis. The current situation sees around 6000 people per year commit suicide, of which almost 75% are men, with those under the age of 45 being the greatest affected (The Independent 2016). According [...]

GW Pharma Stocks Fall

By | January 22nd, 2015|Categories: GW Pharma|

Stocks for GW Pharmaceuticals, the manufacturers of cannabinoid-based medicines, has fallen sharply after a clinical study failed to show their product Sativex was effective in relieving pain directly associated with cancer. GW Pharmaceuticals is a British biopharmaceutical company best-known for its cannabis-based product Sativex, which is the original natural cannabis plant derivative to achieve complete [...]